Sarah Premji, MD

Assistant Director Breast Cancer at Sarah Cannon Research Institute, Medical Oncologist at SCRI Oncology Partners

[Sarah Premji, MD @SPremji7866]

In the blink of an eye - fellowship is over! Grateful to @MayoCancerCare for 3 transformative years of excellent training and mentorship! Beyond excited to join a group I deeply admire at @SCRIOncology who has already warmly welcomed me! @mpgoetz @jonaspaludo @ErikaHamilton9

[Sarah Premji, MD @SPremji7866]

Two days with the @MJHLifeSciences crew in the studio was a blast!

[Sarah Premji, MD @SPremji7866]

@stage4kelly @Breastcancerorg 💯💯💯💯💯💯

[Sarah Premji, MD @SPremji7866]

Absolutely incredible, 11 approvals in half of a year!

Tucatinib is now approved in front line maintainence for HER2+ MBC a win for patients! Kudos to @ErikaHamilton9 and team for their study of HER2CLIMB05!

@SCRIOncology
@SarahCannonDocs

[Tatiana Prowell, MD @tmprowell]

Today’s approval makes 11 in #breastcancer since May 1! Google “FDA oncology approvals” for searchable list of heme/oncology FDA approvals (2006 to now) w/ a concise description of each, in reverse chronological order. A+ for Boards prep or clinical practice. #OncTwitter #bcsm

[OncUpdates @OncUpdates]

🤔Going to #SABCS26?

📍Join Us for the @OncBrothers #AIO event!

🗓️In Person Dec 9th,2026

⭐️Faculty Panel @sdent_cardioonc @hoperugo @ErikaHamilton9 @PTarantinoMD @hmcarthur + DrSaraHurvitz

🔗Register: https://t.co/6jkvKBojn6

#bcsm #OncTwitter #BreastCancer @SABCSSanAntonio

[Sarah Premji, MD @SPremji7866]

I got a chance to sit down with Targeted Oncology for Breast Cancer Awareness Month to discuss clinical trials in the community and a few of the many ongoing trials that may shape how we treat breast cancer!
@SCRIOncology
@SarahCannonDocs

#targetedoncology
#bcsm

[Targeted Oncology @TargetedOnc]

For #BreastCancerAwarenessMonth, Sarah Premji, MD (@SarahCannonDocs @SCRIOncology) discussed community trial access, biomarker-driven drug development, and key #BreastCancer studies to watch.

💬 Full interview: https://t.co/FQ0OMNpSc9

#Oncology #ClinicalTrials | @SPremji7866

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Special time for @SCRIOncology this morning at @SusanGKomen walk in #Nashville!

So fun to be with our community and our patients! We love 💗 them!

[Komal Jhaveri, MD, FACP, FASCO @jhaveri_komal]

Grateful for the growing options to treat ESR1-mutated tumors. This combination was NCCN endorsed and now FDA approved. This pace of progress is exciting for our patients — but our work is far from done! @MSKCancerCenter @OncoAlert #bcsm

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this wonderful profile of Dr. Ann Partridge (@AnnPartridgeMD) in @NewBedfordLight, reflecting on her extraordinary career advancing #BreastCancer care and research, her commitment to young patients, and life as New Bedford’s “first lady.”
https://t.co/z9jJK0beNj

[Rebecca Shatsky, MD @Dr_RShatsky]

Excellent summary of the NEW standard of care in Her2 positive disease. Time to abandon this one size fits all approach! #bcsm #breastcancer

[Abigail Johnston @AMJohnston1315]

New blog post up as I start my 12th (I think) line of treatment today, Trodelvy. https://t.co/QUVz71IWYJ #bcsm

[Yakup Ergün @dr_yakupergun]

Encouraging news for breast cancer✅️

Gedatolisib has received FDA approval for patients with PIK3CA wild-type disease. We already know that outcomes in the PIK3CA-mutant cohort are also very promising. If approval is extended to that population, gedatolisib could become a treatment option in the subsequent setting regardless of PIK3CA mutation status.

Another important question is who should receive the triplet (+palbociclib) and who should receive the doublet.

In the PIK3CA-mutant cohort, palbociclib does not appear to provide an additional PFS benefit, although the triplet achieved a higher ORR. It may therefore still be considered for patients requiring a rapid response. How the FDA label will ultimately be structured for the mutant population remains to be seen.

In the PIK3CA wild-type cohort, PFS was numerically longer with the triplet. I would therefore be more inclined to add palbociclib in pre/perimenopausal patients, those with rapidly progressive disease or substantial visceral burden, and patients with good hematologic tolerance.

For now, the main practical limitation remains its intravenous administration!

[Sarah Premji, MD @SPremji7866]

@DrSAHaddad Congratulations!!!

[Sarah Cannon Docs @SarahCannonDocs]

In a recent @SurvivorNetTeam feature, SCRI’s @SPremji7866 discusses datopotamab deruxtecan, a newly approved targeted therapy for triple negative breast cancer.
Read more: https://t.co/xqKeEny7Wq

[Sarah Premji, MD @SPremji7866]

Thrilled to be a 2026 JCO Editorial Fellow alongside this stellar group!

[Journal of Clinical Oncology @JCO_ASCO]

Join us in honoring the 2026 JCO Editorial Fellows!

The journal’s quality relies on rigorous analysis and scientific integrity. We’re proud to support these oncology fellows as they dive deep into peer review and medical publishing alongside our editor mentors.

Thank you for your dedication to advancing oncology research - @BilalAbidMD, @trishapaulmdmfa, @Spremji7866, @tomkinsoliver

Learn more about becoming an editorial fellow: https://t.co/hf07jZOTaW

[BreastCancersToday @BreastCancersTd]

New Article: ASCO 2026 breast cancer highlights from @SPremji7866, @ErikaHamilton9 et al:
• OPTIMA
• HER2CLIMB-05
• VIKTORIA-1 → gedatolisib shows promise
• SERDs -> progress + open questions
• Supportive care gains
https://t.co/e1BlxcgTMR @SarahCannonDocs

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

#ASCO26 summary in #bcsm led by @SPremji7866 and @SarahCannonDocs

https://t.co/d4tFYkf7wv

[Sarah Premji, MD @SPremji7866]

If you don’t already know… Live From Stage 4 is this amazing podcast by patients for patients and really anyone in the #bcsm community - what an honor it was to sit down with Victoria and Abigail to dive into some of the HR+ MBC updates - we had a great time! @AMJohnston1315
https://t.co/aGDyI1CHfN

[Sarah Premji, MD @SPremji7866]

@allisonoconn @PTarantinoMD So incredibly sorry for your loss ❤️

[Sarah Premji, MD @SPremji7866]

Excited to join @roondoctors early community as a founding physician.

We’re building a digital home for medicine - a trusted space where doctors can connect, collaborate and advance clinical knowledge.

If you’re a US based physician, feel free to join at this link: https://t.co/KrgmkWWrwk